Weiss Ratings Reaffirms “Sell (E+)” Rating for 10x Genomics (NASDAQ:TXG)

10x Genomics (NASDAQ:TXG)‘s stock had its “sell (e+)” rating reiterated by stock analysts at Weiss Ratings in a research note issued on Saturday,Weiss Ratings reports.

Other analysts also recently issued research reports about the company. UBS Group boosted their target price on 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft set a $14.00 price objective on shares of 10x Genomics and gave the stock a “hold” rating in a report on Friday, August 8th. Wall Street Zen cut shares of 10x Genomics from a “buy” rating to a “hold” rating in a research note on Saturday. Piper Sandler started coverage on shares of 10x Genomics in a research note on Thursday, September 11th. They issued a “neutral” rating and a $15.00 price target for the company. Finally, Zacks Research cut 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 5th. Six investment analysts have rated the stock with a Buy rating, eight have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $13.65.

10x Genomics Price Performance

10x Genomics stock opened at $13.35 on Friday. The firm has a market capitalization of $1.66 billion, a P/E ratio of -19.07 and a beta of 2.00. 10x Genomics has a one year low of $6.78 and a one year high of $24.38. The business has a fifty day moving average price of $13.24 and a 200-day moving average price of $10.83.

10x Genomics (NASDAQ:TXG) last announced its quarterly earnings results on Thursday, August 7th. The company reported $0.28 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. 10x Genomics had a negative net margin of 13.13% and a negative return on equity of 12.88%. The firm had revenue of $172.91 million for the quarter, compared to the consensus estimate of $139.36 million. During the same period in the prior year, the firm posted ($0.32) earnings per share. The company’s revenue for the quarter was up 12.9% on a year-over-year basis. 10x Genomics has set its Q3 2025 guidance at EPS. Sell-side analysts expect that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Insider Activity at 10x Genomics

In other 10x Genomics news, CEO Serge Saxonov sold 9,348 shares of the firm’s stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total transaction of $128,908.92. Following the completion of the transaction, the chief executive officer owned 945,892 shares in the company, valued at $13,043,850.68. This trade represents a 0.98% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, insider Benjamin J. Hindson sold 7,486 shares of the stock in a transaction that occurred on Friday, August 22nd. The shares were sold at an average price of $13.79, for a total value of $103,231.94. Following the transaction, the insider owned 440,888 shares of the company’s stock, valued at $6,079,845.52. This represents a 1.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 39,149 shares of company stock worth $539,865. 10.03% of the stock is owned by company insiders.

Hedge Funds Weigh In On 10x Genomics

Large investors have recently made changes to their positions in the company. Orion Porfolio Solutions LLC purchased a new stake in 10x Genomics in the second quarter worth $158,000. Nikko Asset Management Americas Inc. grew its holdings in shares of 10x Genomics by 12.1% in the second quarter. Nikko Asset Management Americas Inc. now owns 6,009,653 shares of the company’s stock worth $69,532,000 after purchasing an additional 646,997 shares during the last quarter. CANADA LIFE ASSURANCE Co increased its stake in 10x Genomics by 167.9% in the 2nd quarter. CANADA LIFE ASSURANCE Co now owns 22,069 shares of the company’s stock worth $256,000 after buying an additional 13,831 shares during the period. Exome Asset Management LLC bought a new stake in 10x Genomics during the 2nd quarter valued at about $1,895,000. Finally, Corient Private Wealth LLC purchased a new stake in 10x Genomics in the 2nd quarter valued at about $597,000. 84.68% of the stock is owned by hedge funds and other institutional investors.

About 10x Genomics

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.